You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物-B(01801.HK)續漲11%屢創上市新高 治療細胞癌新藥研究達主要研究終點
阿思達克 05-15 11:50
信達生物-B(01801.HK)治療細胞癌新藥研究達主要研究終點,該股連續第二天創上市新高,最高見44.7元,現造44元,續漲11%,成交增至524萬股,涉資2.22億元。

信達生物公布,集團與禮來製藥共同開發創新PD-1抑制劑達伯舒(信迪利單抗注射液)一項於中國開展II期ORIENT-2研究-達伯舒用於二線治療晚期或轉移性食管鱗狀細胞癌患者達到總生存期主要研究終點。詳細研究結果將於今年ASCO會議上以壁報討論形式予以發佈。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account